Industry
Biotechnology
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 to recognize folate receptor alpha (FOLR1) with indications, including gynecological, non-small cell lung cancer, renal caner, and others. The company was incorporated in 2018 and is headquartered in Dallas, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 21, 2024 | 9:08 pm
Portfolio Pulse from Benzinga Newsdesk
January 22, 2024 | 11:06 am
Portfolio Pulse from Benzinga Newsdesk
January 19, 2024 | 7:13 pm
Portfolio Pulse from Benzinga Newsdesk
January 17, 2024 | 7:34 pm
Portfolio Pulse from Benzinga Newsdesk
January 16, 2024 | 10:19 pm
Portfolio Pulse from Benzinga Newsdesk
January 16, 2024 | 1:26 pm
Portfolio Pulse from Benzinga Newsdesk
December 05, 2023 | 10:02 pm
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 11:27 am
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:50 pm
Portfolio Pulse from Benzinga Newsdesk
November 13, 2023 | 10:48 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.